These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22963800)

  • 1. Safety of Zostavax™--a cohort study in a managed care organization.
    Baxter R; Tran TN; Hansen J; Emery M; Fireman B; Bartlett J; Lewis N; Saddier P
    Vaccine; 2012 Oct; 30(47):6636-41. PubMed ID: 22963800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoster vaccine live.
    Kockler DR; McCarthy MW
    Pharmacotherapy; 2007 Jul; 27(7):1013-9. PubMed ID: 17594207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study.
    Tseng HF; Liu A; Sy L; Marcy SM; Fireman B; Weintraub E; Baggs J; Weinmann S; Baxter R; Nordin J; Daley MF; Jackson L; Jacobsen SJ;
    J Intern Med; 2012 May; 271(5):510-20. PubMed ID: 22026504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.
    Tseng HF; Smith N; Sy LS; Jacobsen SJ
    Vaccine; 2011 May; 29(20):3628-32. PubMed ID: 21435407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends and disparity in zoster vaccine uptake in a managed care population.
    Hechter RC; Tartof SY; Jacobsen SJ; Smith N; Tseng HF
    Vaccine; 2013 Sep; 31(41):4564-8. PubMed ID: 23928461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
    Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
    Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shingles vaccine.
    Willison CB; Morrison LK; Mendoza N; Tyring SK
    Expert Opin Biol Ther; 2010 Apr; 10(4):631-8. PubMed ID: 20113211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of herpes zoster among children immunized with varicella vaccine: results from a nested case-control study.
    Tseng HF; Smith N; Marcy SM; Sy LS; Chao CR; Jacobsen SJ
    Pediatr Infect Dis J; 2010 Mar; 29(3):205-8. PubMed ID: 19952977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
    Tyring SK; Diaz-Mitoma F; Padget LG; Nunez M; Poland G; Cassidy WM; Bundick ND; Li J; Chan IS; Stek JE; Annunziato PW;
    Vaccine; 2007 Feb; 25(10):1877-83. PubMed ID: 17227688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.
    Tseng HF; Chi M; Smith N; Marcy SM; Sy LS; Jacobsen SJ
    J Infect Dis; 2012 Jul; 206(2):190-6. PubMed ID: 22669900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
    Baxter R; Bartlett J; Fireman B; Marks M; Hansen J; Lewis E; Aukes L; Chen Y; Klein NP; Saddier P
    Am J Epidemiol; 2018 Jan; 187(1):161-169. PubMed ID: 29309521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes zoster vaccine: clinical trial evidence and implications for medical practice.
    Burke MS
    J Am Osteopath Assoc; 2007 Mar; 107(3 Suppl 1):S14-8. PubMed ID: 17488883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
    Tseng HF; Smith N; Harpaz R; Bialek SR; Sy LS; Jacobsen SJ
    JAMA; 2011 Jan; 305(2):160-6. PubMed ID: 21224457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study.
    Ohfuji S; Ito K; Inoue M; Ishibashi M; Kumashiro H; Hirota Y; Kayano E; Ota N
    BMC Infect Dis; 2019 Jan; 19(1):95. PubMed ID: 30691396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.